Evaluation of the K9CATH peptide in the treatment of experimental pulmonary tuberculosis | Zendy

Rossana Tamayo Sosa Alma | Zendy; Manuel del Villar Peacute rez Viacute ctor | Zendy; Barreras Serrano Alberto | Zendy; Hernaacute ndez P Rogelio | Zendy; o | Zendy; Aacute ngel Olivas Valdez Joseacute | Zendy; Tonatiuh Melgarejo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the K9CATH peptide in the treatment of experimental pulmonary tuberculosis

Author(s) -

Rossana Tamayo Sosa Alma,

Manuel del Villar Peacute rez Viacute ctor,

Barreras Serrano Alberto,

Hernaacute ndez P Rogelio,

o,

Aacute ngel Olivas Valdez Joseacute,

Tonatiuh Melgarejo

Publication year - 2012

Publication title -

african journal of microbiology research

Language(s) - English

Resource type - Journals

ISSN - 1996-0808

DOI - 10.5897/ajmr12.1208

Subject(s) - mycobacterium tuberculosis , peptide , tuberculosis , antimicrobial , microbiology and biotechnology , chemistry , minimum inhibitory concentration , in vitro , pulmonary tuberculosis , medicine , biology , biochemistry , pathology

The antimicrobial activity of the peptide K9CATH against Mycobacterium tuberculosis H37Rv in vitro and its therapeutic potential against pulmonary tuberculosis in a murine model was evaluated. By the alamar blue colorimetric assay, a minimum inhibitory concentration (MIC) of 10.66 μg/ml was obtained. Also, K9CATH did not show to be cytotoxic at 32 μg/ml on lung cells (A549). Electron microscopy images obtained of M. tuberculosis treated with the peptide showed disruption of the membrane and condensation of the cytoplasmic content. Mice infected with M. tuberculosis H37Rv and treated with 32 μg/ml of K9CATH for 30 and 60 days showed a significant decrease (p < 0.5) in colony-forming units (CFU) and pneumonic area.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research